MGNX News and Press, MacroGenics Inc. From 02/25/20

Start Time: 16:30 End Time: 17:23 MacroGenics, Inc. (MGNX) Q4 2019 Earnings Conference Call February 25, 2020, 16:30 PM ET Company Participants Scott Koenig - President and CEO Jim Karrels - SVP, CFO and Secretary Anna Krassowska - VP, IR and Corporate Communications Confe...

MacroGenics (NASDAQ: MGNX ): FY GAAP EPS of -$3.16 beats by $0.28 . More news on: MacroGenics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancer First clinical data from Phase 1/2 studies of MGD013, MGC018 and MGD019 anticipated in 2020 Confere...

Rockville, MD, Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release...

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. (TSLA) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad hoc query ...

Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will present...

Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced its corporate and program pri...

MacroGenics (NASDAQ: MGNX ) has filed to offer up to $50M in shares via Cowen. More news on: MacroGenics, Inc., Healthcare stocks news, Read more ...

MacroGenics ( MGNX +3.3% ) has filed its U.S. marketing application seeking approval of margetuximab for the treatment of metastatic HER2-positive breast cancer (combined with chemo). More news on: MacroGenics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has submitted a...